Revenue: As of FY2025, the actual value is USD 824.5 M, beating the estimate of USD 822.69 M.EPS: As of FY2025, the actual value is USD -3.95.EBIT: As of FY2025, the actual value is USD -378.5 M.<h4>Overall Financial Performance</h4><ul><li>Myriad Genetics, Inc. reported a net loss of - $365.9 million in 2025, compared to a net loss of - $127.3 million in 2024.</li></ul><h4>Revenue by Product Category</h4><ul><li>Hereditary Cancer: Revenue increased by 2% to $372.4 million in 2025 from $364.5 million in 2024.</li><li>Tumor Profiling: Revenue decreased by 3% to $121.7 million in 2025 from $125.8 million in 2024, primarily due to the divestment of the EndoPredict business in August 2024.</li><li>Prenatal: Revenue increased by 5% to $186.3 million in 2025 from $177.1 million in 2024.</li><li>Mental Health: Revenue decreased by 15% to $144.1 million in 2025 from $170.2 million in 2024, mainly due to a 20% decrease in average revenue per test following UnitedHealthcare’s policy change on GeneSight test coverage.</li></ul><h4>Testing Volume by Product Category</h4><ul><li>Total testing volume increased by 1% to 1,537 thousand tests in 2025 from 1,520 thousand tests in 2024.</li><li>Hereditary Cancer: Volume increased by 7% to 315 thousand tests in 2025 from 294 thousand tests in 2024.</li><li>Tumor Profiling: Volume decreased by 9% to 48 thousand tests in 2025 from 53 thousand tests in 2024.</li><li>Prenatal: Volume decreased by 4% to 637 thousand tests in 2025 from 666 thousand tests in 2024, driven by a decline in SneakPeek volume.</li><li>Mental Health: Volume increased by 6% to 537 thousand tests in 2025 from 507 thousand tests in 2024.</li></ul><h4>Revenue by Geographical Region</h4><ul><li>U.S. Revenue: $768.0 million in 2025 compared to $769.5 million in 2024.</li><li>Rest of World (RoW) Revenue: $56.5 million in 2025 compared to $68.1 million in 2024.</li></ul><h4>Operating Expenses</h4><ul><li>Cost of Revenue: Decreased by - $4.3 million (-2%) to $247.9 million in 2025 from $252.2 million in 2024, maintaining 30.1% of total revenue in both years.</li><li>Research and Development Expense: Decreased by - $6.6 million (-6%) to $106.8 million in 2025 from $113.4 million in 2024, primarily due to lower compensation-related expenses.</li><li>Sales and Marketing Expense: Decreased by - $3.3 million (-1%) to $280.8 million in 2025 from $284.1 million in 2024.</li><li>General and Administrative Expense: Decreased by - $19.1 million (-7%) to $256.8 million in 2025 from $275.9 million in 2024, largely due to a - $9.8 million decrease in amortization for previously impaired intangible assets.</li><li>Legal Settlements: Zero in 2025, compared to - $21.3 million in 2024, which included a reversal of expense for a contingent payment related to the Ravgen settlement.</li><li>Goodwill and Long-lived Asset Impairment Charges: Increased significantly to $319.4 million in 2025 from $56.8 million in 2024. This included goodwill impairment charges of $234.7 million and intangible asset impairment charges of $82.0 million related to the Women’s Health and Mental Health reporting units in 2025.</li><li>Other Expense, net: Increased to - $7.9 million in 2025 from $0 million in 2024, mainly due to higher interest expense from the new term loan.</li></ul><h4>Cash Flow</h4><ul><li>Net cash provided by operating activities: Increased to $1.8 million in 2025 from - $8.7 million in 2024, driven by changes in working capital.</li><li>Net cash used in investing activities: Increased to - $27.4 million in 2025 from - $11.9 million in 2024, as 2024 included cash inflows from investment maturities and the sale of the EndoPredict business.</li><li>Net cash provided by financing activities: Increased to $64.2 million in 2025 from - $7.4 million in 2024, primarily due to proceeds from the new Credit Facility, partially offset by repayment of the prior ABL Facility and debt issuance costs.</li></ul><h4>Outlook / Guidance</h4>Myriad Genetics, Inc. expects to discontinue sales of its EndoPredict test in the United States during the first half of 2026. The company anticipates R&amp;D investment to increase in 2026, with a focus on the Cancer Care Continuum. The change in UnitedHealthcare’s coverage for the GeneSight test is expected to continue negatively affecting Mental Health revenue in future periods.

Myriad Genetic | 10-K: FY2025 Revenue Beats Estimate at USD 824.5 M